

## Raltegravir Pediatric Granules Formulation

Version 5.0      Revision Date: 26.09.2023      SDS Number: 20463-00023      Date of last issue: 20.03.2023  
Date of first issue: 09.10.2014

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Raltegravir Pediatric Granules Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
117 16th Road  
1685 Halfway house, Midrand, South Africa

Telephone : +27 11 655 3000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Serious eye damage, Category 1	H318: Causes serious eye damage.
Reproductive toxicity, Category 2	H361d: Suspected of damaging the unborn child.
Specific target organ toxicity - single exposure, Category 3	H335: May cause respiratory irritation.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H318 Causes serious eye damage.  
H335 May cause respiratory irritation.  
H361d Suspected of damaging the unborn child.

## Raltegravir Pediatric Granules Formulation

Version 5.0      Revision Date: 26.09.2023      SDS Number: 20463-00023      Date of last issue: 20.03.2023  
 Date of first issue: 09.10.2014

Precautionary statements :

**Prevention:**

P201 Obtain special instructions before use.  
 P261 Avoid breathing dust.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Hazardous components which must be listed on the label:

Raltegravir

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Raltegravir	871038-72-1	Eye Dam. 1; H318 Repr. 2; H361d STOT SE 3; H335	>= 20 - < 30
Ammonium hydroxide	1336-21-6 215-647-6 007-001-01-2	Acute Tox. 4; H302 Skin Corr. 1B; H314 Eye Dam. 1; H318 Aquatic Acute 1; H400 Aquatic Chronic 2; H411  M-Factor (Acute aquatic toxicity): 1	>= 0,1 - < 0,25

For explanation of abbreviations see section 16.

## Raltegravir Pediatric Granules Formulation

Version 5.0      Revision Date: 26.09.2023      SDS Number: 20463-00023      Date of last issue: 20.03.2023  
Date of first issue: 09.10.2014

---

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention immediately.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

- Risks : Causes serious eye damage.  
May cause respiratory irritation.  
Suspected of damaging the unborn child.
- Contact with dust can cause mechanical irritation or drying of the skin.

#### 4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.
- 

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing : None known.
-

## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
5.0	26.09.2023	20463-00023	Date of first issue: 09.10.2014

---

media

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Fluorine compounds  
Metal oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air.  
Add excess liquid to allow the material to enter into solution.  
Soak up with inert absorbent material.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and dis-

## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
5.0	26.09.2023	20463-00023	Date of first issue: 09.10.2014

---

posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

- |                         |   |   |
|-------------------------|---|---|
| Technical measures      | : | Static electricity may accumulate and ignite suspended dust causing an explosion.<br>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.  |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation.   |
| Advice on safe handling | : | Avoid breathing dust.<br>Do not swallow.<br>Do not get in eyes.<br>Avoid prolonged or repeated contact with skin.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Keep container tightly closed.<br>Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.<br>Minimize dust generation and accumulation.<br>Keep container closed when not in use.<br>Keep away from heat and sources of ignition.<br>Take precautionary measures against static discharges.<br>Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  |

### 7.2 Conditions for safe storage, including any incompatibilities

- |   |   |  |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations. |
| Advice on common storage                      | : | Do not store with the following product types:<br>Strong oxidizing agents  |

### 7.3 Specific end use(s)

- |                 |   |                   |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

## Raltegravir Pediatric Granules Formulation

Version 5.0      Revision Date: 26.09.2023      SDS Number: 20463-00023      Date of last issue: 20.03.2023  
 Date of first issue: 09.10.2014

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

##### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Raltegravir	871038-72-1	TWA	1000 µg/m <sup>3</sup> (OEB 1)	Internal
Cellulose	9004-34-6	OEL-RL	10 mg/m <sup>3</sup>	ZA OEL
Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents				

##### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Ammonium hydroxide	Fresh water	0,001 mg/l
	Freshwater - intermittent	0,008 mg/l
	Marine water	0,001 mg/l
	Soil	0,022 mg/kg dry weight (d.w.)

#### 8.2 Exposure controls

##### Engineering measures

Minimize workplace exposure concentrations.  
 Apply measures to prevent dust explosions.  
 Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).  
 If sufficient ventilation is unavailable, use with local exhaust ventilation.

##### Personal protective equipment

Eye/face protection : Wear the following personal protective equipment:  
 Chemical resistant goggles must be worn.  
 If splashes are likely to occur, wear:  
 Face-shield

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.  
 Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
5.0	26.09.2023	20463-00023	Date of first issue: 09.10.2014

---

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type (P)

---

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

Appearance	:	powder
Colour	:	off-white
Odour	:	odourless
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

#### 9.2 Other information

**Raltegravir Pediatric Granules Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
5.0	26.09.2023	20463-00023	Date of first issue: 09.10.2014

---

Flammability (liquids)	:	No data available
Molecular weight	:	No data available
Particle size	:	No data available

---

**SECTION 10: Stability and reactivity****10.1 Reactivity**

Not classified as a reactivity hazard.

**10.2 Chemical stability**

Stable under normal conditions.

**10.3 Possibility of hazardous reactions**

Hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
---------------------	---	--

**10.4 Conditions to avoid**

Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
---------------------	---	---

**10.5 Incompatible materials**

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

**10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

---

**SECTION 11: Toxicological information****11.1 Information on toxicological effects**

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

**Acute toxicity**

Not classified based on available information.

**Components:****Raltegravir:**

Acute oral toxicity	:	LD50 (Mouse, male and female): > 2.000 mg/kg
---------------------	---	--

**Ammonium hydroxide:**

Acute oral toxicity	:	LD50 (Rat): 350 mg/kg
---------------------	---	-----------------------

Acute inhalation toxicity	:	Assessment: Corrosive to the respiratory tract.
---------------------------	---	---

---



**Raltegravir Pediatric Granules Formulation**

Version 5.0      Revision Date: 26.09.2023      SDS Number: 20463-00023      Date of last issue: 20.03.2023  
Date of first issue: 09.10.2014

---

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Raltegravir:**

Species : Rabbit  
Result : No skin irritation

**Ammonium hydroxide:**

Species : Rabbit  
Result : Corrosive after 3 minutes to 1 hour of exposure  
Remarks : Based on national or regional regulation.

**Serious eye damage/eye irritation**

Causes serious eye damage.

**Components:****Raltegravir:**

Species : Bovine cornea  
Result : Severe irritation

**Ammonium hydroxide:**

Result : Irreversible effects on the eye  
Remarks : Based on skin corrosivity.

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Raltegravir:**

Test Type : Local lymph node assay (LLNA)  
Species : Mouse  
Result : negative

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Raltegravir:**

Genotoxicity in vitro : Test Type: reverse mutation assay  
Result: negative  
  
Test Type: Alkaline elution assay  
Test system: rat hepatocytes

## Raltegravir Pediatric Granules Formulation

Version 5.0      Revision Date: 26.09.2023      SDS Number: 20463-00023      Date of last issue: 20.03.2023  
 Date of first issue: 09.10.2014

Result: negative

Test Type: Chromosomal aberration  
 Method: OECD Test Guideline 473  
 Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
 Species: Mouse  
 Result: negative

Test Type: Chromosomal aberration  
 Method: OECD Test Guideline 475  
 Result: negative

### Ammonium hydroxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Raltegravir:

Species : Mouse, male and female  
 Exposure time : 104 weeks  
 Result : negative

### Reproductive toxicity

Suspected of damaging the unborn child.

### Components:

#### Raltegravir:

Effects on fertility : Test Type: Fertility/early embryonic development  
 Species: Rat, male and female  
 Application Route: Oral  
 General Toxicity - Parent: NOAEL: 600 mg/kg body weight  
 Result: negative

Effects on foetal development : Species: Rat  
 Application Route: Oral  
 General Toxicity Maternal: NOAEL:  $\geq$  600 mg/kg body weight  
 Teratogenicity: LOAEL F1: 300 mg/kg body weight  
 Symptoms: Skeletal malformations  
 Result: positive

Species: Rabbit  
 General Toxicity Maternal: NOAEL:  $\geq$  1.000 mg/kg body weight  
 Teratogenicity: NOAEL:  $\geq$  1.000 mg/kg body weight  
 Result: negative

Reproductive toxicity - As- : Some evidence of adverse effects on development, based on

## Raltegravir Pediatric Granules Formulation

Version 5.0      Revision Date: 26.09.2023      SDS Number: 20463-00023      Date of last issue: 20.03.2023  
 Date of first issue: 09.10.2014

Assessment      animal experiments.

### STOT - single exposure

May cause respiratory irritation.

#### Components:

##### Raltegravir:

Exposure routes      : Inhalation  
 Target Organs      : Respiratory Tract  
 Assessment      : May cause respiratory irritation.

### STOT - repeated exposure

Not classified based on available information.

#### Repeated dose toxicity

#### Components:

##### Raltegravir:

Species      : Dog  
 NOAEL      : 90 mg/kg  
 Application Route      : Oral  
 Exposure time      : 371 d  
 Symptoms      : Vomiting

Species      : Rat  
 NOAEL      : 30 mg/kg  
 LOAEL      : 120 mg/kg  
 Application Route      : Oral  
 Exposure time      : 189 d  
 Target Organs      : Stomach

Species      : Mouse  
 NOAEL      : 50 mg/kg  
 LOAEL      : 500 mg/kg  
 Application Route      : Oral  
 Exposure time      : 14 Weeks  
 Target Organs      : Stomach

Species      : Rat  
 NOAEL      : 50 mg/kg  
 LOAEL      : 200 mg/kg  
 Application Route      : Oral  
 Exposure time      : 8 Weeks  
 Target Organs      : Stomach

#### Aspiration toxicity

Not classified based on available information.

#### Experience with human exposure

#### Components:

##### Raltegravir:

## Raltegravir Pediatric Granules Formulation

Version 5.0      Revision Date: 26.09.2023      SDS Number: 20463-00023      Date of last issue: 20.03.2023  
 Date of first issue: 09.10.2014

|| Ingestion : Symptoms: Nausea, Diarrhoea, Headache, Fever, Rash, Skin irritation

### SECTION 12: Ecological information

#### 12.1 Toxicity

##### Components:

##### **Raltegravir:**

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
		LC50 (Cyprinodon variegatus (sheepshead minnow)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): 66 mg/l Exposure time: 96 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): 3,8 mg/l Exposure time: 96 h Method: OECD Test Guideline 201
Toxicity to microorganisms	:	EC50 : > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
		NOEC : 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Toxicity to fish (Chronic toxicity)	:	NOEC: 9,3 mg/l Exposure time: 33 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC: 9,5 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

##### **Ammonium hydroxide:**

|| Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0,89 mg/l

## Raltegravir Pediatric Granules Formulation

Version 5.0      Revision Date: 26.09.2023      SDS Number: 20463-00023      Date of last issue: 20.03.2023  
 Date of first issue: 09.10.2014

	Exposure time: 96 h Test substance: Neutralised product
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 101 mg/l Exposure time: 48 h
M-Factor (Acute aquatic toxicity)	: 1
Toxicity to fish (Chronic toxicity)	: NOEC: 0,0135 mg/l Exposure time: 73 d Species: Oncorhynchus mykiss (rainbow trout) Test substance: Neutralised product
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC: 0,961 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Remarks: Based on data from similar materials

### 12.2 Persistence and degradability

#### Components:

##### **Raltegravir:**

Biodegradability	: Result: rapidly degradable Biodegradation: 50 % Exposure time: 9 d Method: OECD Test Guideline 302B
Stability in water	: Hydrolysis: < 10 %(5 d) Method: OECD Test Guideline 111

### 12.3 Bioaccumulative potential

#### Components:

##### **Raltegravir:**

Partition coefficient: n-octanol/water	: log Pow: -0,328
--	-------------------

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment	: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
------------	--

### 12.6 Other adverse effects

#### Product:

Endocrine disrupting poten-	: The substance/mixture does not contain components consid-
-----------------------------	---

## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
5.0	26.09.2023	20463-00023	Date of first issue: 09.10.2014

---

tial

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

---

### SECTION 13: Disposal considerations

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

### SECTION 14: Transport information

#### 14.1 UN number

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

#### 14.2 UN proper shipping name

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

#### 14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

#### 14.4 Packing group

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
5.0	26.09.2023	20463-00023	Date of first issue: 09.10.2014

---

**RID** : Not regulated as a dangerous good  
**IMDG** : Not regulated as a dangerous good  
**IATA (Cargo)** : Not regulated as a dangerous good  
**IATA (Passenger)** : Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined  
 DSL : not determined  
 IECSC : not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

---

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H302 : Harmful if swallowed.  
 H314 : Causes severe skin burns and eye damage.  
 H318 : Causes serious eye damage.  
 H335 : May cause respiratory irritation.  
 H361d : Suspected of damaging the unborn child.  
 H400 : Very toxic to aquatic life.  
 H411 : Toxic to aquatic life with long lasting effects.

### Full text of other abbreviations

Acute Tox. : Acute toxicity  
 Aquatic Acute : Short-term (acute) aquatic hazard  
 Aquatic Chronic : Long-term (chronic) aquatic hazard  
 Eye Dam. : Serious eye damage  
 Repr. : Reproductive toxicity  
 Skin Corr. : Skin corrosion

## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
5.0	26.09.2023	20463-00023	Date of first issue: 09.10.2014

STOT SE : Specific target organ toxicity - single exposure  
 ZA OEL : South Africa. The Regulations for Hazardous Chemical Agents, Occupational Exposure Limits  
 ZA OEL / OEL-RL : Occupational Exposure Limit Restricted limit - 8- hour exposure or equivalent (12 hour shifts)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Eye Dam. 1	H318
Repr. 2	H361d
STOT SE 3	H335

### Classification procedure:

Calculation method
Calculation method
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
5.0	26.09.2023	20463-00023	Date of first issue: 09.10.2014

---

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN